ArticleResuscitation plus2026
Wolf Creek XVIII Part 4: innovations in ECPR technology.
Article in Resuscitation plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wolf Creek XVIII Part 1: advancing resuscitation science.Resuscitation plus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 50th Anniversary Wolf Creek XVIII Conference was hosted by the Max Harry Weil Institute for Critical Care Research and Innovation in Ann Arbor, Michigan, USA on June 19-21, 2025. "Innovations in ECPR Technology" was one topic of focused presentation and discussion by invited panelists and conference participants made up of international academic and industry scientists as well as thought leaders in the field of cardiac arrest resuscitation. This panel was part of the conference agenda in order to update the auditorium on the current state of the art of ECPR increasingly offered by specialized centers worldwide but still far away from routine use. In view of the ongoing high mortality and morbidity of patients treated with CPR following cardiac arrest, ECPR arises as a potential promise to improve this challenge, however many questions with respect to patient selection, implementation and the required related technical and educational resources are currently not solved and remain as relevant barriers. Moreover, current ECPR does not follow standardized protocols and is therefore a highly individualized therapy of each performing center. This is a relevant barrier in order to conduct trials with larger and more homogenous groups of patients. Despite the tempting option to overcome the shortcomings of CPR, the field of ECPR primarily requires targeted research with focus on community studies and the rationale implementation of extracorporeal circulation in the CPR scenario.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.